165 related articles for article (PubMed ID: 38331776)
41. Nanog suppression enhanced the chemosensitivity of human non-small-cell lung cancer cells to Cisplatin and inhibited cell migration.
Najafzadeh B; Motafakkerazad R; Najafi S; Amini M; Alemohammad H; Vasefifar P; Baradaran B
Pathol Res Pract; 2022 May; 233():153869. PubMed ID: 35398618
[TBL] [Abstract][Full Text] [Related]
42. Combined Effects of Programmed Cell Death-1 Blockade and Endostar on Brain Metastases of Lung Cancer.
Qi X; Zhao Y; Yang S; Sun Y; Liu H; Liu P; Feng S; Tui H; Yuan Z; Yang J; Bu H
Anticancer Agents Med Chem; 2023; 23(6):709-716. PubMed ID: 36043757
[TBL] [Abstract][Full Text] [Related]
43. HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer.
Eguchi R; Wakabayashi I
Oncol Rep; 2020 Jul; 44(1):14-28. PubMed ID: 32319650
[TBL] [Abstract][Full Text] [Related]
44. Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.
Shao N; Song L; Sun X
Mol Cell Biochem; 2021 Jun; 476(6):2253-2267. PubMed ID: 33570734
[TBL] [Abstract][Full Text] [Related]
45. Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging.
Zhang FL; Gao EY; Shu RB; Wang H; Zhang Y; Sun P; Li M; Tang W; Jiang BQ; Chen SQ; Cui FB
Asian Pac J Cancer Prev; 2015; 16(15):6765-8. PubMed ID: 26434908
[TBL] [Abstract][Full Text] [Related]
46. Effect of endostar combined with cisplatin on expression of VEGF and Sema3A of Lewis lung cancer rats.
Feng P; Zhang ZL; Zhang ZH; Zhang XL; Xiang F; Tang JH; Xiang BL
Asian Pac J Trop Med; 2013 Jan; 6(1):57-60. PubMed ID: 23317887
[TBL] [Abstract][Full Text] [Related]
47. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
Wang D; Xiang DB; Yang XQ; Chen LS; Li MX; Zhong ZY; Zhang YS
Lung Cancer; 2009 Dec; 66(3):298-304. PubMed ID: 19324449
[TBL] [Abstract][Full Text] [Related]
48. Changes of activated circulating endothelial cells and survivin in patients with non-small cell lung cancer after antiangiogenesis therapy.
Wang J; Huang C; Wei XY; Qi DL; Gong LQ; Mu HY; Yao Q; Li K
Chin Med J (Engl); 2008 Nov; 121(22):2234-40. PubMed ID: 19080323
[TBL] [Abstract][Full Text] [Related]
49. Cancer-associated fibroblasts promote migration and invasion of non-small cell lung cancer cells via METTL3-mediated RAC3 m
Chen M; Zhang Q; Zheng S; Guo X; Cao L; Ren Y; Qian Y; Wang M; Wu X; Xu K
Int J Biol Sci; 2023; 19(5):1616-1632. PubMed ID: 37056933
[TBL] [Abstract][Full Text] [Related]
50. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.
Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC
Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715
[TBL] [Abstract][Full Text] [Related]
51. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
52. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
Ju ZS; Sun B; Bao D; Zhang XF
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788
[TBL] [Abstract][Full Text] [Related]
53. Treatment with EGCG in NSCLC leads to decreasing interstitial fluid pressure and hypoxia to improve chemotherapy efficacy through rebalance of Ang-1 and Ang-2.
Deng PB; Hu CP; Xiong Z; Yang HP; Li YY
Chin J Nat Med; 2013 May; 11(3):245-53. PubMed ID: 23725836
[TBL] [Abstract][Full Text] [Related]
54. Inhibitory effect of endostar in combination with radiotherapy in a mouse model of human CNE2 nasopharyngeal carcinoma.
Zhou N; Hu G; Mei Q; Qiu H; Long G; Chen C; Guoqing H
J Huazhong Univ Sci Technolog Med Sci; 2011 Feb; 31(1):62-66. PubMed ID: 21336725
[TBL] [Abstract][Full Text] [Related]
55. LncRNA ITGB2-AS1 promotes cisplatin resistance of non-small cell lung cancer by inhibiting ferroptosis via activating the FOSL2/NAMPT axis.
Chen H; Wang L; Liu J; Wan Z; Zhou L; Liao H; Wan R
Cancer Biol Ther; 2023 Dec; 24(1):2223377. PubMed ID: 37370246
[TBL] [Abstract][Full Text] [Related]
56. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
57. Endostar regulates EMT, migration and invasion of lung cancer cells through the HGF-Met pathway.
Shen Y; Chen Q; Li L
Mol Cell Probes; 2019 Jun; 45():57-64. PubMed ID: 31096000
[TBL] [Abstract][Full Text] [Related]
58. Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth.
Li XQ; Shang BY; Wang DC; Zhang SH; Wu SY; Zhen YS
Cancer Lett; 2011 Feb; 301(2):212-20. PubMed ID: 21216091
[TBL] [Abstract][Full Text] [Related]
59. LncRNA SNHG12 Decreases Non-Small Cell Lung Cancer Cell Sensitivity to Cisplatin by Repressing miR-525-5p and Promoting XIAP.
Tan D; Wang S; Zhang P; Peng C; Wu T
Ann Clin Lab Sci; 2023 Jan; 53(1):64-75. PubMed ID: 36889771
[TBL] [Abstract][Full Text] [Related]
60. Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration.
Xu H; Lv D; Meng Y; Wang M; Wang W; Zhou C; Zhou S; Chen X; Yang H
Ann Palliat Med; 2020 Mar; 9(2):298-307. PubMed ID: 32075401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
